News
First photoactive drug to fight Parkinson’s disease
Experts from the Institute of Neurosciences of the University of Barcelona (UB), the Bellvitge Biomedical Research Institute (IDIBELL) and Universitat Autònoma de Barcelona (UAB) design the first photoactive drug to fight Parkinson’s disease.
New non-invasive biomarker for diagnosis and prognosis in male sterility
Researchers from the Human Molecular Genetics group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Sara Larriba, have identified a new non-invasive biomarker of the presence of sperm in the testis of azoospermic men, who represent 10% of the cases of male sterility. The work, published in the prestigious international journal Human Reproduction, […]
Green light to REMAB, a new IDIBELL Spin-Off
REMAB Therapeutics, the new IDIBELL Spin-off, was officially launched by the end of April 2018. The company has doctors Rafael Mañez (IP) and Daniel Bello, from the research group on innate immunity and pathology of the critical patient, as founding partners, together with IDIBELL. REMAB’s main objective is the development of a new molecule for […]
IDIBELL hosts the ”Marie Sklodowska-Curie Individual Actions, 2018 call” Information Day
On May 10th, the “Marie Skłodowska-Curie Individual actions, 2018 call” infoday was held in the facilities of Duran i Reynals Hospital. The session, which was co-organized by the Bellvitge Biomedical Research of Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Agency for the Management of University and Research Grants (AGAUR), filled the auditorium […]
A new drug shows preclinical efficacy in Rett syndrome
A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models. The study, led by Dr. Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and […]
New collaboration agreement between IDIBELL and IMLCFC
The Bellvitge Biomedical Research Institute (IDIBELL) has recently signed a collaboration agreement with the Institute of Legal Medicine and Forensic Sciences of Catalonia (IMLCFC). The main objective of this agreement is to establish a collaboration between both institutions to jointly develop programs and activities linked to biomedical research, as well as to achieve significant improvements […]
How does BRCA1 breast cancer become resistant to chemotherapy?
Researchers of the proCURE program of the Catalan Institute of Oncology, Oncobell-IDIBELL, have recently published a scientific paper in which they describe the genetic mechanisms by which a breast tumor associated to a mutated BRCA1 gene becomes resistant to chemotherapy. Breast cancers that appear in women with BRCA1 mutations usually present a poor prognosis […]
Scientists identify a potential treatment for Hereditary Hemorrhagic Telangiectasia
Collaboration between basic and clinical research groups at Bellvitge leads to the first therapy for this disease The work of researchers Francesc Viñals and Mariona Graupera at the Bellvitge Biomedical Research Institute (IDIBELL, Oncobell program) – Catalan Institute of Oncology (ICO, ProCURE program) – University of Barcelona, together with Dr. Antoni Riera-Mestre (IDIBELL, Bellvitge University […]
The EPICUP Project receives a Pfizer Foundation Innovation award
The development of the EPICUP epigenomic tool, capable of improving the diagnosis of metastases of unknown origin, has been awarded the Prize for Scientific Innovation in its Clinical Research modality by the Pfizer Foundation, which was given to the first author of the study, Dr. Sebastian Morán, at an event held at the Hospital la […]